235 related articles for article (PubMed ID: 17456683)
1. Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels.
Punke MA; Friederich P
Anesth Analg; 2007 May; 104(5):1256-64, tables of contents. PubMed ID: 17456683
[TBL] [Abstract][Full Text] [Related]
2. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
4. Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine.
Kim SE; Ahn HS; Choi BH; Jang HJ; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Hahn SJ
J Pharmacol Exp Ther; 2007 May; 321(2):753-62. PubMed ID: 17312186
[TBL] [Abstract][Full Text] [Related]
5. Lipophilic and stereospecific interactions of amino-amide local anesthetics with human Kv1.1 channels.
Punke MA; Friederich P
Anesthesiology; 2008 Nov; 109(5):895-904. PubMed ID: 18946303
[TBL] [Abstract][Full Text] [Related]
6. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
7. The facilitating effect of systemic administration of Kv7/M channel blocker XE991 on LTP induction in the hippocampal CA1 area independent of muscarinic activation.
Song MK; Cui YY; Zhang WW; Zhu L; Lu Y; Chen HZ
Neurosci Lett; 2009 Sep; 461(1):25-9. PubMed ID: 19463897
[TBL] [Abstract][Full Text] [Related]
8. [Epileptic seizures from etomidate? The human Kv1.1 potassium channel in humans].
Friederich P; Trellakis S; Urban BW
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Feb; 36(2):100-4. PubMed ID: 11269011
[TBL] [Abstract][Full Text] [Related]
9. A possible link between KCNQ2- and STXBP1-related encephalopathies: STXBP1 reduces the inhibitory impact of syntaxin-1A on M current.
Devaux J; Dhifallah S; De Maria M; Stuart-Lopez G; Becq H; Milh M; Molinari F; Aniksztejn L
Epilepsia; 2017 Dec; 58(12):2073-2084. PubMed ID: 29067685
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II regulates neuronal excitability via phosphatidylinositol 4,5-bisphosphate-dependent modulation of Kv7 (M-type) K+ channels.
Zaika O; Lara LS; Gamper N; Hilgemann DW; Jaffe DB; Shapiro MS
J Physiol; 2006 Aug; 575(Pt 1):49-67. PubMed ID: 16777936
[TBL] [Abstract][Full Text] [Related]
11. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
[TBL] [Abstract][Full Text] [Related]
12. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
Bentzen BH; Schmitt N; Calloe K; Dalby Brown W; Grunnet M; Olesen SP
Neuropharmacology; 2006 Nov; 51(6):1068-77. PubMed ID: 16904708
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole.
Ahn HS; Choi JS; Choi BH; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Hahn SJ
Neuroscience; 2005; 133(4):1007-19. PubMed ID: 15964489
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HERG channels by the local anaesthetic articaine.
Siebrands CC; Friederich P
Eur J Anaesthesiol; 2007 Feb; 24(2):148-53. PubMed ID: 16938156
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Kv7/M Channel Currents by the Local Anesthetic Chloroprocaine.
Zhang F; Cheng Y; Li H; Jia Q; Zhang H; Zhao S
Pharmacology; 2015; 96(3-4):124-30. PubMed ID: 26202459
[TBL] [Abstract][Full Text] [Related]
16. Concatemers of brain Kv1 channel alpha subunits that give similar K+ currents yield pharmacologically distinguishable heteromers.
Sokolov MV; Shamotienko O; Dhochartaigh SN; Sack JT; Dolly JO
Neuropharmacology; 2007 Aug; 53(2):272-82. PubMed ID: 17637465
[TBL] [Abstract][Full Text] [Related]
17. Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
Punke MA; Friederich P
Anesthesiology; 2004 Aug; 101(2):430-8. PubMed ID: 15277926
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
19. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR
J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569
[TBL] [Abstract][Full Text] [Related]
20. Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model.
Zheng Q; Fang D; Liu M; Cai J; Wan Y; Han JS; Xing GG
Pain; 2013 Mar; 154(3):434-448. PubMed ID: 23352759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
